DALLAS, Aug. 6, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Anadys Pharmaceuticals Inc. (Nasdaq:ANDS). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Anadys Pharmaceuticals Inc. (Nasdaq:ANDS) should be of particular interest to pharmaceutical companies: Dynavax Technologies Corp. (Nasdaq:DVAX), Gilead Sciences Inc. (Nasdaq:GILD), Human Genome Sciences Inc. (Nasdaq:HGSI) and Bristol-Myers Squibb Co. (NYSE:BMY).
It is available at: http://www.beaconequity.com/i/ANDS
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Anadys Pharmaceuticals Inc. (ANDS) is a developer, manufacturer and marketer of novel therapies through proprietary biopharmacological technologies for the treatment of hepatitis C. The Company focuses its marketing efforts on the improvement of the patients with the hepatitis C virus, which it believes is under-served.
In the report, the analyst notes:
"ANA598 is the Company's lead candidate non-nucleoside polymerase inhibitor for the treatment of hepatitis C virus (HCV). On July 30, the Company announced its phase II trial ANA598 protocol was completed which includes combinations with pegylated interferon-alpha and ribaviran in patients suffering from hepatitis C. Initial results of the phase II trials are expected to be available by the fourth quarter, with further information expected during the first two quarters of calendar 2010.
"If approved by the U.S. Food and Drug Administration (FDA), revenue for ANA598 could conceivably reach more than $500 million at its market saturation. Pharmaceutical companies with revenue close to this revenue level include Cephalon Inc. (Nasdaq:CEPH), which trades at a market capitalization of $3.73 billion, and King Pharmaceuticals (Nasdaq:KG)..."
To read the entire report, visit: http://www.beaconequity.com/i/ANDS
See what investors are saying about all these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.